Final DREAMseq results favor first-line immunotherapy for melanoma
Michael Atkins, MD, FASCO, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, provides the background and final results of the DREAMseq trial (NCT02224781). Although targeted BRAF/MEK inhibition therapy and combined PD-1/CTLA-4 blockade immunotherapy with nivolumab/ipilimumab have both been FDA approved in patients with BRAFV600-mutant metastatic melanoma, optimal treatment sequencing remains unknown. Recruiting patients with metastatic treatment-naïve mutant melanoma, results showed greater overall survival benefit with immunotherapy as initial treatment, followed by targeted therapy when necessary. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
